indication directory

Alzheimer's disease clinical trial intelligence

Trials are included only when the source condition or controlled indication mapping directly matches this disease area. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

Directory type

indication

Association rule

source condition

NCT00954252

Source recordAI-normalized

Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects

CHF 5074, developed by CERESPIR, is positioned as a novel gamma-secretase modulator aimed at treating Alzheimer's disease by reducing amyloid-beta levels. The Alzheimer's disease market is projected to grow significantly, driven by increasing prevalence and demand for effective therapies. The competitive landscape includes several established players and emerging biotech firms focused on similar mechanisms. Given the high unmet need in Alzheimer's treatment, successful outcomes in this trial could enhance CERESPIR's market position and attract potential partnerships or acquisition interest. Diligence should focus on the safety profile and pharmacokinetic data to assess viability for further development.

AI analysis

Indication: Alzheimer's Disease

Modality: small molecule

Target: Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.

Sponsor: CERESPIR

Source URL: ClinicalTrials.gov

Source updated: Feb 10, 2015

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Alzheimer's Disease

View original source fields

Condition raw: Alzheimer's Disease

Condition normalized: Alzheimer's Disease

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.

Target normalized: Gamma-secretase modulator, specifically targeting amyloid precursor protein (APP) processing to reduce amyloid-beta (Aβ) production.

Open report

NCT07105709

Source recordAI-normalized

A Multi-Centre, Single Arm, Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of GSK4527226 (AL101) in Participants With Early Alzheimer's Disease

GSK4527226 is positioned within a competitive landscape of Alzheimer's Disease therapies, particularly targeting early-stage patients with mild cognitive impairment and mild dementia. The market for Alzheimer's treatments is substantial, with increasing demand for effective disease-modifying therapies. GSK's collaboration with Alector Inc. may enhance its development capabilities and market reach. The success of this trial could provide GSK with a significant foothold in the Alzheimer's market, which is currently underserved, particularly for early intervention strategies.

AI analysis

Indication: Alzheimer's Disease

Modality: small molecule

Target: GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Feb 02, 2026

Ingested: Jun 12, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Alzheimer's Disease

View original source fields

Condition raw: Alzheimer's Disease

Condition normalized: Alzheimer's Disease

Modality raw: small molecule

Modality normalized: small molecule

Target raw: GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.

Target normalized: GSK4527226 (AL101) is being investigated for its potential effects on cognitive decline in early Alzheimer's Disease, targeting mechanisms associated with amyloid pathology.

Open report

NCT01832350

Source recordAI-normalized

Clinical Protocol of a Prospective, Open-label Study to Assess the Safety and Efficacy of Nuedexta (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Alzheimer's Disease

The primary objective of this study is to test the hypothesis that Nuedexta (20/10) administered orally will reduce Pseudobulbar Affect (PBA) frequency and severity (CNS-Lability Scale and PLACS), with satisfactory safety and high tolerability in patients with Alzheimer's Disease (AD). The primary objective will be evaluated using a study endpoint at 1, 13, 26 weeks after initiation of treatment. The secondary objective of this study is to evaluate the benefit of treatment with Nuedexta (20/10) on cognition and functionality as demonstrated in the Rey Auditory Verbal Learning Test (RAVLT), Trail making A and B, Wechsler Memory Scale (WMS) logical memory and delayed recall, Controlled Oral Word Association (COWA), Clinical Dementia Rating (CDR), Neuropsychiatric Inventory (NPI), Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCSADL) and the 11-item Alzheimer's Disease Assessment Scale-Cognitive subscore (ADAS-Cog11).

AI analysis

Indication: Alzheimer's Disease

Modality: small molecule

Target: Nuedexta (20/10)

Sponsor: St. Joseph's Hospital and Medical Center, Phoenix

Source URL: ClinicalTrials.gov

Source updated: Oct 29, 2019

Ingested: Jun 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Alzheimer's Disease

View original source fields

Condition raw: Alzheimer's Disease, Pseudobulbar Affect (PBA)

Condition normalized: Alzheimer's Disease, Pseudobulbar Affect (PBA)

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Nuedexta (20/10)

Target normalized: Nuedexta (20/10)

Open report

NCT02640092

Source recordAI-normalized

Longitudinal Evaluation of [18F]GTP1 as a PET Radioligand for Imaging Tau in the Brain of Patients With Prodromal, Mild, and Moderate Alzheimer's Disease Compared to Healthy Volunteers

Genentech's [18F]GTP1 is positioned within the growing market for Alzheimer's disease diagnostics, particularly in imaging tau pathology. The completion of this Phase 1 study suggests a potential pathway for further development and commercialization, especially as the demand for accurate diagnostic tools in Alzheimer's disease increases. The competitive landscape includes other tau imaging agents, but [18F]GTP1's unique properties may provide differentiation. Diligence should focus on the regulatory pathway and potential partnerships for broader clinical application.

AI analysis

Indication: Alzheimer's Disease

Modality: small molecule

Target: Tau protein in the brain

Sponsor: Genentech, Inc.

Source URL: ClinicalTrials.gov

Source updated: Dec 23, 2019

Ingested: Jun 08, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Alzheimer's Disease

View original source fields

Condition raw: Alzheimer's Disease

Condition normalized: Alzheimer's Disease

Modality raw: small molecule

Modality normalized: small molecule

Target raw: Tau protein in the brain

Target normalized: Tau protein in the brain

Open report

NCT00605059

Source recordAI-normalized

Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

The clinical trial aimed to evaluate [123I] AV94 as a potential imaging biomarker for beta-amyloid burden in Alzheimer's disease using SPECT imaging. Conducted by the Institute for Neurodegenerative Disorders, the study involved 20 Alzheimer's patients and 10 healthy controls to assess the uptake and washout of the imaging agent.

AI analysis

Indication: Alzheimer Disease

Modality: small molecule

Target: Beta-amyloid protein deposition in Alzheimer's disease

Sponsor: Institute for Neurodegenerative Disorders

Source URL: ClinicalTrials.gov

Source updated: Oct 06, 2010

Ingested: May 23, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by conditions: Alzheimer Disease

View original source fields

Condition raw: Alzheimer Disease

Condition normalized: Alzheimer Disease

Modality raw: Alzheimer Disease

Modality normalized: small molecule

Target raw: Beta-amyloid protein deposition in Alzheimer's disease

Target normalized: Beta-amyloid protein deposition in Alzheimer's disease

Open report